Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01247571 · OUTCOME

Progression-free Survival

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From start of treatment to time of progression or death, assessed up to 5 years

What was measured

Progression-free survival is the period from study entry until disease progression, death or date of last contact

Analysis population: Eligible and Treated Patients

Groups in this outcome

Pazopanib

Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib19

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pazopanib2.0Not reported1.63.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.6
        upper Limit
        3.6
        value
        2.0
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
Progression-free survival is the period from study entry until disease progression, death or date of last contact
dispersion Type
95% Confidence Interval
groups
  1. description
    Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
    id
    OG000
    title
    Pazopanib
param Type
MEDIAN
population Description
Eligible and Treated Patients
reporting Status
POSTED
time Frame
From start of treatment to time of progression or death, assessed up to 5 years
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice